PresentationGood morning, everyone. I hope everyone's had a good conference week. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Cliff Zhang, a member of the Healthcare Investment Banking team based in New York. Our next presenting company is Jade Biosciences. And speaking on behalf of the company, I'm pleased to welcome CEO, Tom Frohlich. Please give it up for Tom.Tom FrohlichCEO & Director Thanks, Cliff. It really -- it's a pleasure to be here. Thanks for hosting us at the conferenc ...

PresentationWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Oculis. And presenting on behalf of the company, we have CEO, Riad Sherif. Riad, over to you.Riad SherifCEO & Director Thank you, Tessa. Very happy to be here and very pleased to introduce Oculis to you. Thank you, Tessa and JPM for a great meeting and conference. So we are a public company, NASDAQ listed, here o ...

Core Insights - BioNTech is shifting its focus back to oncology, leveraging its mRNA technology for cancer treatment [2][5] - Goldman Sachs upgraded BioNTech from Neutral to Buy, citing the company's potential in cancer treatment [2][5] - BioNTech has a substantial cash reserve of $17 billion to support late-stage development [2][5] Company Performance - BioNTech has delivered five billion doses of its COVID-19 vaccine globally, reaching over 180 countries [3][5] - The company is conducting 25 clinical trials with 16 clinical programs currently in progress [3][5] - Despite a recent stock price decrease of 2.80%, the current price is $106.07, with a market capitalization of approximately $25.51 billion [4]

The J.P. Morgan Healthcare Conference held in San Francisco, California from 12 January to 15 January 2026 saw a key investment theme centred on driving value through internal pipeline prioritisation and billion-dollar licensing agreements, rather than the typically expected large biopharmaceutical mergers and acquisitions (M&A) announcements. Lower interest rates and Trump-era deregulation drove momentum in large biopharmaceutical M&As in 2025, with reduced uncertainty around the impact of Trump’s tarif ...

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Genuity Corp. (the "Underwriter") as the sole underwriter and sole bookrunner pursuant to which the Underwriter has agreed to purchase for resale 10,384,616 units ...

PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poste ...

Laughing Water Capital, an investment management company, released its fourth-quarter 2025 investor letter. In the quarter, Laughing Water Capital returned ~6.8%, bringing the full-year returns to ~3.9% net of fees and expenses. In comparison, the SP500TR and R2000 returned approximately 2.7% and 2.2%, respectively, in the quarter, and finished the year up by 17.9% and 12.8%, respectively. A copy of the letter can be downloaded here. The Fund outperformed the indexes last year, but it has lagged behind the ...

Core Points - NRx Pharmaceuticals, Inc. will hold its 2025 Annual Meeting on March 23, 2026, at 10:00 a.m. Eastern Time in a virtual-only format [1] - The record date for stockholders entitled to vote at the meeting is set for February 12, 2026 [1] - The deadline for stockholder proposals and nominations is January 26, 2026, due to the timing of the meeting [4][6] Company Information - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [8] - The company is developing NRX-100 and NRX-101, with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression and NRX-101 receiving Breakthrough Therapy Designation for suicidal bipolar depression [8] - NRx has filed an Abbreviated New Drug Application for NRX-100 and initiated a New Drug Application filing for the same drug [8]

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws related to Travere, specifically whether the company and its executives made materially false or misleading statements or omitted important information regarding its business and operations [1][2] Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3] - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for providing the most monetary relief to investors [3]

Core Viewpoint - BridgeBio Pharma, Inc. has announced the pricing of $550 million in 0.75% convertible senior notes due 2033, aimed at raising funds for various corporate purposes, including repurchasing existing convertible notes and shares [1][3][8]. Group 1: Offering Details - The offering consists of $550 million aggregate principal amount of 0.75% convertible senior notes, with an option for initial purchasers to buy an additional $82.5 million [1][2]. - The expected net proceeds from the sale are approximately $538.4 million, or $619.3 million if the option is fully exercised [2]. - The notes will bear interest at a rate of 0.75% per year, payable semi-annually, and will mature on February 1, 2033 [5][8]. Group 2: Use of Proceeds - The net proceeds will be used to repurchase or settle obligations related to the Company's 2.50% convertible senior notes due 2027 and for general corporate purposes [3]. - Approximately $82.5 million of cash on hand will be used to repurchase about 1.1 million shares of common stock from certain purchasers of the notes [4]. Group 3: Conversion and Redemption Terms - The initial conversion rate is set at 9.0435 shares per $1,000 principal amount of notes, equating to an initial conversion price of approximately $110.58 per share, representing a 45% premium over the last reported sale price of $76.26 [6][8]. - The Company may redeem the notes starting February 6, 2030, under certain conditions, at a redemption price equal to 100% of the principal amount plus accrued interest [7][10]. Group 4: Company Overview - BridgeBio Pharma is focused on developing transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [13].